Abstract
Prostate cancer remains the most common non-cutaneous malignancy among American men. Since the advent of PSA testing, most men are diagnosed with localized disease, but a proportion of men will be diagnosed with metastatic disease, many will eventually receive chemotherapy with docetaxel and prednisone. However, responses are not durable and all men will ultimately progress on this treatment. As such, continued efforts are geared towards the discovery of new agents and mechanisms of targeting prostate cancer. Angiogenesis has been shown to play an important role in tumorigenesis, proliferation and metastasis in prostate cancer. Here we discuss the major angiogenic signaling pathway involving VEGF in prostate cancer progression, and the role of various promising agents that targeting this pathway. This includes bevacizumab, thalidomide and its analogs, tyrosine kinase inhibitors sorafenib and AZD2171, and other inhibitors of angiogenic signaling pathways. Results of key clinical trials associated with the use of these agents and future directions are discussed herein.
Keywords: Angiogenesis, Prostate Cancer, Bevacizumab, Thalidomide, Lenalidomide, AZD2171, Sorafenib
Current Molecular Pharmacology
Title: VEGF Inhibitors and Prostate Cancer Therapy
Volume: 2
Author(s): Jeanny B. Aragon-Ching and William L. Dahut
Affiliation:
Keywords: Angiogenesis, Prostate Cancer, Bevacizumab, Thalidomide, Lenalidomide, AZD2171, Sorafenib
Abstract: Prostate cancer remains the most common non-cutaneous malignancy among American men. Since the advent of PSA testing, most men are diagnosed with localized disease, but a proportion of men will be diagnosed with metastatic disease, many will eventually receive chemotherapy with docetaxel and prednisone. However, responses are not durable and all men will ultimately progress on this treatment. As such, continued efforts are geared towards the discovery of new agents and mechanisms of targeting prostate cancer. Angiogenesis has been shown to play an important role in tumorigenesis, proliferation and metastasis in prostate cancer. Here we discuss the major angiogenic signaling pathway involving VEGF in prostate cancer progression, and the role of various promising agents that targeting this pathway. This includes bevacizumab, thalidomide and its analogs, tyrosine kinase inhibitors sorafenib and AZD2171, and other inhibitors of angiogenic signaling pathways. Results of key clinical trials associated with the use of these agents and future directions are discussed herein.
Export Options
About this article
Cite this article as:
Aragon-Ching B. Jeanny and Dahut L. William, VEGF Inhibitors and Prostate Cancer Therapy, Current Molecular Pharmacology 2009; 2 (2) . https://dx.doi.org/10.2174/1874467210902020161
DOI https://dx.doi.org/10.2174/1874467210902020161 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nerve Growth Factor Receptors and Signaling in Breast Cancer
Current Cancer Drug Targets Gonadotropin-Releasing Hormone (GnRH) Receptors in Tumors: a New Rationale for the Therapeutical Application of GnRH Analogs in Cancer Patients?
Current Cancer Drug Targets n-3 Polyunsaturated Fatty Acids as Signal Transduction Modulators and Therapeutical Agents in Cancer
Current Signal Transduction Therapy Alternative Splicing in Chronic Myeloid Leukemia (CML): A Novel Therapeutic Target?
Current Cancer Drug Targets MicroRNAs (miRNAs) in Colorectal Cancer: From Aberrant Expression Towards Therapy
Current Pharmaceutical Design Resveratrol Promotes HIV-1 Tat Accumulation <i>via</i> AKT/FOXO1 Signaling Axis and Potentiates Vorinostat to Antagonize HIV-1 Latency
Current HIV Research Molecular and Cellular Activities of Vitamin E Analogues
Mini-Reviews in Medicinal Chemistry Interaction and Structural Modification of Topoisomerase IIα by Peptidyl Prolyl Isomerase, pin1: An In Silico Study
Protein & Peptide Letters Pd Catalyzed N1/N4 Arylation of Piperazine for Synthesis of Drugs, Biological and Pharmaceutical Targets: An Overview of Buchwald Hartwig Amination Reaction of Piperazine in Drug Synthesis
Current Organic Synthesis Editorial (Thematic Issue: Nanocarriers Based on Natural Polymers as Platforms for Drug and Gene Delivery Applications)
Current Pharmaceutical Design Targeting BMP9-Promoted Human Osteosarcoma Growth by Inactivation of Notch Signaling
Current Cancer Drug Targets Alpha-Emitters for Immuno-Therapy: A Review of Recent Developments from Chemistry to Clinics
Current Topics in Medicinal Chemistry The PKB/AKT Pathway in Cancer
Current Pharmaceutical Design Virus, Oncolytic Virus and Human Prostate Cancer
Current Cancer Drug Targets Are Hsp90 Inhibitors Good Candidates Against Covid-19?
Current Protein & Peptide Science Bradykinin Receptors in Ischemic Injury
Current Neurovascular Research Mechanical Imaging - a Technology for 3-D Visualization and Characterization of Soft Tissue Abnormalities: A Review
Current Medical Imaging Application of Monoclonal Antibodies as Cancer Therapy in Solid Tumors
Current Clinical Pharmacology Females Live Longer than Males: Role of Oxidative Stress
Current Pharmaceutical Design Novel Therapeutic Approaches in Pancreatic Cancer Based on Genomic Alterations
Current Pharmaceutical Design